Propel Bio Management’s Zevra Therapeutics ZVRA Stock Holding History

Propel Bio Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.64M	Sell	253,544 -28,874	-10%	-$321K	1.9%	18
2026 Q1	$2.64M	Buy	282,418 +218,735	+343%	+$1.97M	1.66%	23
2025 Q4	$571K	Sell	63,683 -168,191	-73%	-$1.59M	0.49%	19
2025 Q3	$2.21M	Hold	231,874	–	–	2.21%	14
2025 Q2	$2.04M	Buy	231,874 +52,000	+29%	+$422K	2.48%	10
2025 Q1	$1.35M	Hold	179,874	–	–	1.57%	12
2024 Q4	$1.5M	Hold	179,874	–	–	1.49%	13
2024 Q3	$1.25M	Buy	+179,874	New	+$1.22M	0.72%	15

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Propel Bio Management's ZVRA Position: Q2 2026 in Review

Propel Bio Management reduced its Zevra Therapeutics (ZVRA) stake by 10% in Q2 2026, selling an estimated $321K and leaving 253,544 shares worth $3.64M. The position accounts for 1.9% of the portfolio, ranked #18.

Propel Bio Management first reported a position in ZVRA in Q3 2024 and has held it in 8 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Propel Bio Management held 253,544 shares of Zevra Therapeutics worth $3.64M as of Q2 2026.
Propel Bio Management sold 28,874 Zevra Therapeutics shares in Q2 2026, an estimated $321K.
Zevra Therapeutics made up 1.9% of Propel Bio Management's portfolio in Q2 2026, its #18 holding.
Propel Bio Management first reported a position in Zevra Therapeutics in Q3 2024 and has held it in 8 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.